2 Information about molnupiravir

Marketing authorisation indication

2.1

Molnupiravir (Lagevrio, Merck Sharp & Dohme) is indicated 'for the treatment of mild to moderate coronavirus disease 2019 (COVID‑19) in adults with a positive SARS‑CoV‑2 diagnostic test and who have at least one risk factor for developing severe illness'.

Dosage in the marketing authorisation

Price

2.3

The list price for molnupiravir is £590 per pack containing 40 capsules (excluding VAT; company submission).